OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
19 oct. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Oct. 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that its Chief Scientific Officer Nicolas Poirier will present the latest...
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
13 oct. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, Oct. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that three abstracts have been accepted for presentation at the Society for...
OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”
12 oct. 2021 01h30 HE
|
OSE Immunotherapeutics
R&D Day to highlight the Company’s strategy on its leading clinical programs and emerging firs-in-class portfolio in immuno-oncology;Presentations by leading clinicians to feature the latest data...
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
11 oct. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, Oct. 11, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced today that it has received notice of allowance from the European Patent Office...
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colorectal Tumors
30 sept. 2021 12h30 HE
|
OSE Immunotherapeutics
Dosing of first patient in the expansion phase triggers a milestone payment of €8 million from Boehringer Ingelheim to OSE Immunotherapeutics.Data from the dose escalation Step 1 of the Phase 1 trial...
OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021
27 sept. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that it will host a virtual and in-person R&D Day on Tuesday, October...
OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update
21 sept. 2021 12h00 HE
|
OSE Immunotherapeutics
Positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) after ICI failure.Positive Phase 1 dose escalation results for BI 765063 (CD47/SIRPα pathway) as monotherapy or in...
OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
20 sept. 2021 07h45 HE
|
OSE Immunotherapeutics
NANTES, France, Sept. 20, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the positive final results of its Phase 3 trial of neoepitope-based...
OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the European Society for Medical Oncology (ESMO) Virtual Congress 2021
20 sept. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, Sept. 20, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the presentation of Phase 3 clinical results of Tedopi® today at 13:30 CEST in a...
Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
16 sept. 2021 12h00 HE
|
OSE Immunotherapeutics
BI 765063, a first-in-class SIRPα inhibitor in the SIRPα/CD47 “Don’t eat me” pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.Data from...